Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:FATE NASDAQ:NBIX NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$61.89+3.0%$52.92$44.12▼$78.48$5.79B1.711.51 million shs2.05 million shsFATEFate Therapeutics$2.99+2.4%$2.14$0.91▼$3.21$340.35M2.514.29 million shs3.39 million shsNBIXNeurocrine Biosciences$174.10-0.1%$156.87$122.14▼$175.02$17.52B0.391.08 million shs922,828 shsVIRVir Biotechnology$10.02-0.2%$9.37$4.16▼$11.66$1.69B1.622.20 million shs1.57 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+3.01%+9.83%+19.39%+24.53%+18.67%FATEFate Therapeutics+2.40%+23.55%+51.01%+160.00%+161.14%NBIXNeurocrine Biosciences-0.09%+2.41%+6.24%+33.00%+35.98%VIRVir Biotechnology-0.20%-3.47%+15.84%+9.27%+82.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$61.89+3.0%$52.92$44.12▼$78.48$5.79B1.711.51 million shs2.05 million shsFATEFate Therapeutics$2.99+2.4%$2.14$0.91▼$3.21$340.35M2.514.29 million shs3.39 million shsNBIXNeurocrine Biosciences$174.10-0.1%$156.87$122.14▼$175.02$17.52B0.391.08 million shs922,828 shsVIRVir Biotechnology$10.02-0.2%$9.37$4.16▼$11.66$1.69B1.622.20 million shs1.57 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+3.01%+9.83%+19.39%+24.53%+18.67%FATEFate Therapeutics+2.40%+23.55%+51.01%+160.00%+161.14%NBIXNeurocrine Biosciences-0.09%+2.41%+6.24%+33.00%+35.98%VIRVir Biotechnology-0.20%-3.47%+15.84%+9.27%+82.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.58Moderate Buy$67.789.51% UpsideFATEFate Therapeutics 2.29Hold$5.1371.40% UpsideNBIXNeurocrine Biosciences 2.96Moderate Buy$187.527.71% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.88108.33% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, NBIX, VIR, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026CRSPCRISPR Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$80.006/24/2026NBIXNeurocrine Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)6/23/2026NBIXNeurocrine Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/12/2026CRSPCRISPR Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.006/11/2026CRSPCRISPR Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$60.006/11/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.006/8/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/3/2026NBIXNeurocrine Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.006/2/2026NBIXNeurocrine Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$213.005/29/2026NBIXNeurocrine Biosciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$180.00 ➝ $183.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,700.65N/AN/A$20.17 per share3.07FATEFate Therapeutics$6.65M52.41N/AN/A$1.80 per share1.66NBIXNeurocrine Biosciences$2.86B6.12$5.01 per share34.77$32.63 per share5.34VIRVir Biotechnology$68.56M24.65N/AN/A$5.50 per share1.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)FATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)NBIXNeurocrine Biosciences$478.60M$6.4926.8317.500.6921.55%19.79%13.82%7/29/2026 (Estimated)VIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest CRSP, NBIX, VIR, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026CRSPCRISPR Therapeutics-$1.1966N/AN/AN/A$7.11 millionN/A7/29/2026Q2 2026NBIXNeurocrine Biosciences$2.17N/AN/AN/A$877.34 millionN/A5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96FATEFate TherapeuticsN/A5.855.85NBIXNeurocrine BiosciencesN/A2.932.85VIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%FATEFate Therapeutics97.54%NBIXNeurocrine Biosciences92.59%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%FATEFate Therapeutics4.74%NBIXNeurocrine Biosciences4.60%VIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.50 millionOptionableFATEFate Therapeutics550116.56 million111.03 millionOptionableNBIXNeurocrine Biosciences2,000100.55 million95.93 millionOptionableVIRVir Biotechnology580168.65 million163.76 millionOptionableCRSP, NBIX, VIR, and FATE HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SAJuly 3, 2026 | marketbeat.comOP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIRJune 30, 2026 | marketbeat.comWhy Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps?June 29, 2026 | kalkinemedia.comKVir Biotechnology (NASDAQ:VIR) Draws Attention Amid Pipeline FocusJune 22, 2026 | kalkinemedia.comKVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 22, 2026 | marketbeat.comMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00June 11, 2026 | marketbeat.comVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10, 2026 | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10, 2026 | businesswire.comWINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIRJune 10, 2026 | marketbeat.comBarclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 20262 Space and Defense Stocks Turning Backlogs Into Revenue GrowthBy Nathan Reiff | June 25, 20263 Rate-Ready Stocks for the New Fed Chair’s First Big TestBy Chris Markoch | June 16, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 2026CRSP, NBIX, VIR, and FATE Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$61.89 +1.81 (+3.01%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$62.44 +0.56 (+0.90%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Fate Therapeutics NASDAQ:FATE$2.99 +0.07 (+2.40%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.50%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Neurocrine Biosciences NASDAQ:NBIX$174.10 -0.16 (-0.09%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$175.70 +1.60 (+0.92%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Vir Biotechnology NASDAQ:VIR$10.02 -0.02 (-0.20%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$9.61 -0.41 (-4.13%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore 2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong How TeraWulf’s Anthropic Deal Booted Up a $19B AI Empire Small-Cap ETFs Poised for Big Growth as Rate Outlook Shifts KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
